Table 1.
Patient characteristics in the training and test cohorts
| Clinical characteristics |
Training cohort (n = 55)
|
Test cohort (n = 18)
|
||||
|
MH
|
Non-MH
|
P value
|
MH
|
Non-MH
|
P value
|
|
| Age (year) | 27.32 ± 11.73 | 34.81 ± 10.93 | 0.007 | 31.67 ± 8.50 | 40.92 ± 13.91 | 0.158 |
| Gender, n (%) | 0.384 | 0.316 | ||||
| Male | 16 (84.21) | 25 (69.44) | 6 (100.00) | 8 (66.67) | ||
| Female | 3 (15.79) | 11 (30.56) | 0 (0.00) | 4 (33.33) | ||
| Disease duration, months | 27.11 (23.50) | 48.58 (43.50) | 0.021 | 25.67 (3.00) | 49.83 (37.00) | 0.11 |
| Montreal location, n (%) | 0.715 | 0.761 | ||||
| L1 | 13 (68.42) | 20 (55.56) | 4 (66.67) | 7 (58.33) | ||
| L3 | 4 (21.05) | 12 (33.33) | 2 (33.33) | 4 (33.33) | ||
| L1 + L4 | 1 (5.26) | 3 (8.33) | 0 (0.00) | 1 (8.33) | ||
| L3 + L4 | 1 (5.26) | 1 (2.78) | 0 (0.00) | 0 (0.00) | ||
| Montreal behavior, n (%) | 0.219 | 0.187 | ||||
| B1 | 15 (78.95) | 21 (58.33) | 4 (66.67) | 3 (25.00) | ||
| B2 | 4 (21.05) | 12 (33.33) | 1 (16.67) | 7 (58.33) | ||
| B3 | 0 (0.00) | 3 (8.33) | 1 (16.67) | 2 (16.67) | ||
| Perianal involvement, n (%) | 13 (68.42) | 10 (27.78) | 0.009 | 1 (16.67) | 3 (25.00) | 1.000 |
| Treatment history, n (%) | ||||||
| 5-aminosalicylic acid | 2 (10.53) | 5 (13.89) | 1.00 | 0 (0.00) | 0 (0.00) | 1.000 |
| Steroids | 4 (21.05) | 15 (41.67) | 0.218 | 2 (33.33) | 5 (41.67) | 1.000 |
| Immunomodulator | 4 (21.05) | 19 (52.78) | 0.048 | 2(33.33) | 5 (41.67) | 1.000 |
| Anti-TNF agent | 17 (89.47) | 27 (75.00) | 0.357 | 4 (66.67) | 9 (75.00) | 1.000 |
| Smoking history, n (%) | 3 (15.79) | 6 (16.67) | 1.000 | 3 (50.00) | 3 (25.00) | 0.596 |
| CDAI, mean (IQR) | 63.51 (31.09) | 92.84 (89.14) | 0.589 | 51.72 (35.21) | 82.96 (62.13) | 0.200 |
| BMI (mean ± SD) | 20.98 ± 3.28 | 21.15 ± 3.73 | 0.937 | 23.75 ± 5.06 | 20.60 ± 1.99 | 0.250 |
| WBC (× 109/L) | 5.69 ± 1.56 | 5.97 ± 1.92 | 0.586 | 5.50 ± 2.40 | 5.08 ± 1.64 | 0.779 |
| NLR | 1.67 ± 0.70 | 2.47 ± 1.11 | 0.006 | 1.93 ± 1.17 | 3.80 ± 5.71 | 0.335 |
| HB (g/L) | 139.58 ± 11.79 | 120.19 ± 27.90 | 0.004 | 136.83 ± 15.94 | 132.08 ± 23.51 | 0.664 |
| HCT (%) | 42.07 ± 3.50 | 37.12 ± 7.34 | 0.004 | 41.05 ± 4.81 | 39.61 ± 6.49 | 0.638 |
| ALB (g/L) | 42.55 ± 2.85 | 39.07 ± 4.75 | 0.006 | 42.60 ± 1.41 | 38.87 ± 5.24 | 0.068 |
| CRP (mg/dL) | 2.56 (1.44) | 9.86 (8.38) | 0.000 | 1.51 (0.24) | 9.00 (10.64) | 0.067 |
| CPT (μg/g) | 348.02 (455.37) | 513.29 (410.31) | 0.012 | 349.45 (374.54) | 677.13 (258.78) | 0.111 |
ALB: Albumin; BMI: Body mass index; CDAI: Clinical disease activity index; CPT: Calprotectin; CRP: C-reactive protein; HB: Haemoglobin; HCT: Haematocrit; NLR: Neutrophil-to-lymphocyte ratio; TNF: Tumor necrosis factor; WBC: White blood cell.